• Product name
    Anti-VEGF Receptor 3 antibody
    See all VEGF Receptor 3 primary antibodies
  • Description
    Rabbit polyclonal to VEGF Receptor 3
  • Host species
  • Specificity
    In Western blots, this antibody shows a moderate cross-reactivity with VEGFR2/KDR and a weak cross-reactivity with VEGFR1/FLT1.
  • Tested applications
    Suitable for: Flow Cyt, IHC-Fr, ICC/IF, ELISA, WB, IPmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant fragment corresponding to Human VEGF Receptor 3. Recombinant human soluble VEGFR3/FLT4 protein (110 kDa) (D1-D7).
    Database link: P35916



Our Abpromise guarantee covers the use of ab10284 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use a concentration of 1 - 5 µg/ml.

ab171870 - Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody.

IHC-Fr Use at an assay dependent concentration.
ICC/IF Use at an assay dependent concentration.
ELISA Use a concentration of 1 - 5 µg/ml.
WB Use a concentration of 0.5 - 1 µg/ml. Predicted molecular weight: 164 kDa.
IP Use a concentration of 1 - 5 µg/ml. PubMed: 19366703


  • Function
    Receptor for VEGFC. Has a tyrosine-protein kinase activity.
  • Tissue specificity
    Placenta, lung, heart, and kidney, does not seem to be expressed in pancreas and brain.
  • Involvement in disease
    Defects in FLT4 are the cause of lymphedema hereditary type 1A (LMPH1A) [MIM:153100]; also known as Nonne-Milroy lymphedema or Milroy disease. Hereditary lymphedema is a chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment.
    Note=Defects in FLT4 are found in juvenile hemangioma. Juvenile hemangiomas are the most common tumors of infancy, occurring as many as 10% of all births. These benign vascular lesions enlarge rapidly during the first year of life by hyperplasia of endothelial cells and attendant pericytes, and then spontaneously involute over a period of years, leaving loose fibrofatty tissue.
  • Sequence similarities
    Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Cellular localization
  • Information by UniProt
  • Database links
  • Alternative names
    • EC antibody
    • flt 4 antibody
    • FLT-4 antibody
    • FLT4 antibody
    • FLT41 antibody
    • Fms related tyrosine kinase 4 antibody
    • Fms-like tyrosine kinase 4 antibody
    • LMPH1A antibody
    • PCL antibody
    • Soluble VEGFR3 variant 1 antibody
    • Soluble VEGFR3 variant 2 antibody
    • Soluble VEGFR3 variant 3 antibody
    • Tyrosine protein kinase receptor FLT4 antibody
    • Tyrosine-protein kinase receptor FLT4 antibody
    • Vascular endothelial growth factor receptor 3 antibody
    • Vascular endothelial growth factor receptor 3 precursor antibody
    • VEGF R3 antibody
    • VEGFR 3 antibody
    • VEGFR-3 antibody
    • VEGFR3 antibody
    • VGFR3_HUMAN antibody
    see all


  • Flow Cytometry analysis of human dermal lymphatic endothelial cells (HDLEC) labelling VEGF Receptor 3 with ab10284.

  • Immunohistochemistry (Frozen sections) analysis of human spleen tissue labelling VEGF Receptor 3 with ab10284.

  • Immunocytochemistry/Immunofluorescence analysis of human VEGF Receptor 3 transfected MG63 cells labelling VEGF Receptor 3 (red) with ab10284 (D). A and C are negative controls with secondary antibody only. B uses a monoclonal antibody specific for VEGF Receptor 3.

  • Serum-starved porcine aortic endothelial cells were incubated with recombinant VEGF proteins, and the phosphorylation status of VEGFRs or Akt was analyzed from cell lysates. The effect of VEGF-D?N?C and C25L on the phosphorylation of VEGFR-3 in PAE-Flt4 cells at 5, 15, and 30 minute time points. Cell lysates were immunoprecipitated using ab10284 and analyzed by immunoblotting with an anti phosphotyrosine antibody. Equal loading was confirmed using ab10284.


This product has been referenced in:
  • Toivanen PI  et al. Novel vascular endothelial growth factor D variants with increased biological activity. J Biol Chem 284:16037-48 (2009). IP ; Pig . Read more (PubMed: 19366703) »
See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab10284.
Please use the links above to contact us or submit feedback about this product.


Sign up